Kestra Investment Management LLC Grows Position in Cencora, Inc. (NYSE:COR)

Kestra Investment Management LLC grew its stake in shares of Cencora, Inc. (NYSE:COR) by 46.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,441 shares of the company’s stock after purchasing an additional 1,087 shares during the quarter. Kestra Investment Management LLC’s holdings in Cencora were worth $773,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in COR. Swedbank AB boosted its stake in shares of Cencora by 2.3% during the third quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after purchasing an additional 31,104 shares during the period. Blue Trust Inc. boosted its stake in shares of Cencora by 108.7% during the third quarter. Blue Trust Inc. now owns 2,776 shares of the company’s stock valued at $625,000 after purchasing an additional 1,446 shares during the period. Capital Investment Advisors LLC boosted its stake in shares of Cencora by 35.4% during the third quarter. Capital Investment Advisors LLC now owns 1,334 shares of the company’s stock valued at $300,000 after purchasing an additional 349 shares during the period. Northwest Investment Counselors LLC purchased a new stake in shares of Cencora during the third quarter valued at approximately $70,000. Finally, Whittier Trust Co. boosted its stake in shares of Cencora by 1.0% during the third quarter. Whittier Trust Co. now owns 7,812 shares of the company’s stock valued at $1,758,000 after purchasing an additional 81 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

COR opened at $241.37 on Wednesday. The stock has a fifty day simple moving average of $238.75 and a two-hundred day simple moving average of $237.41. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. The company has a market cap of $46.65 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts predict that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. Cencora’s dividend payout ratio is currently 31.29%.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on COR shares. Wells Fargo & Company increased their price objective on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Evercore ISI upped their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.